SML1928
UM-164 trifluoroacetate salt
≥98% (HPLC)
别名:
2-[[6-[4-(2-Hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-N-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-5-thiazolecarboxamide trifluoroacetate salt
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to beige
溶解性
H2O: 10 mg/mL, clear
储存温度
2-8°C
SMILES字符串
OCCN(CC1)CCN1C2=CC(NC3=NC=C(C(NC4=CC(NC(C5=CC(C(F)(F)F)=CC=C5)=O)=CC=C4C)=O)S3)=NC(C)=N2
InChI
1S/C30H31F3N8O3S/c1-18-6-7-22(37-27(43)20-4-3-5-21(14-20)30(31,32)33)15-23(18)38-28(44)24-17-34-29(45-24)39-25-16-26(36-19(2)35-25)41-10-8-40(9-11-41)12-13-42/h3-7,14-17,42H,8-13H2,1-2H3,(H,37,43)(H,38,44)(H,34,35,36,39)
InChI key
ANEBQUSWQAQFQB-UHFFFAOYSA-N
相关类别
生化/生理作用
UM-164 is a potent dual c-Src/p38 kinase inhibitor that exhibits potent anti-TNBC activity in xenograft models. UM-164 inhibits p38 kinase and binds to an inactive c-Src conformation. UM-164 has a high therapeutic index in vivo.
potent dual c-Src/p38 kinase inhibitor that exhibits potent anti-TNBC activity
警示用语：
Warning
危险声明
危险分类
Eye Irrit. 2 - Skin Irrit. 2
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
此项目有
历史批次信息供参考:
Rabia A Gilani et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 22(20), 5087-5096 (2016-05-08)
c-Src has been shown to play a pivotal role in breast cancer progression, metastasis, and angiogenesis. In the clinic, however, the limited efficacy and high toxicity of existing c-Src inhibitors have tempered the enthusiasm for targeting c-Src. We developed a
Frank E Kwarcinski et al.
ACS chemical biology, 11(5), 1296-1304 (2016-02-20)
In the kinase field, there are many widely held tenets about conformation-selective inhibitors that have yet to be validated using controlled experiments. We have designed, synthesized, and characterized a series of kinase inhibitor analogues of dasatinib, an FDA-approved kinase inhibitor
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持